Pharmacokinetic Study to Evaluate the Extent of Systemic Absorption of PEP005
This study has been completed.
Sponsor:
Peplin
Information provided by:
Peplin
ClinicalTrials.gov Identifier:
NCT00544258
First received: October 14, 2007
Last updated: May 22, 2008
Last verified: May 2008
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Detailed Description:
The purpose of this study is to determine the extent of systemic absorption of PEP005 when applied topically for the treatment of actinic keratoses.
Condition | Intervention | Phase |
---|---|---|
Actinic Keratoses |
Drug: PEP005 |
Phase 1 |
Study Type: | Interventional |
Study Design: | Endpoint Classification: Safety Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
Official Title: | A Phase I, Pharmacokinetic Study to Evaluate the Extent of Systemic Absorption of PEP005, When Applied as 0.05% PEP005 Topical Gel to a 100 cm2 (5 cm x 20 cm) Contiguous Actinic Keratosis(AK) Treatment Area on the Extensor (Dorsal Aspect) Forearm. |
Resource links provided by NLM:
Further study details as provided by Peplin:
Primary Outcome Measures:
- To evaluate the extent of systemic absorption of PEP005 when applied as 0.05% Topical Gel on two consecutive days (Day 1 and Day 2) to a 100 cm2 (5 cm x 20 cm) contiguous AK treatment area on the extensor (dorsal aspect) forearm.
Secondary Outcome Measures:
- To evaluate the safety and tolerability of two consecutive days of application of 0.05% PEP005 Topical Gel, when applied to a 100 cm2 (5 cm x 20 cm) contiguous AK treatment area on the extensor (dorsal aspect) forearm.
Enrollment: | 8 |
Study Start Date: | October 2007 |
Study Completion Date: | May 2008 |
Primary Completion Date: | May 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Experimental: 1
Two days consecutive days of application of 0.05% PEP005 Topical Gel to a 100cm2 contiguous AK treatment area of the arm.
|
Drug: PEP005 |
Detailed Description:
Actinic keratoses (AK) is a common skin condition characterized by rough, scaly patches or sores on the top layer of the skin which if left untreated can progress to skin cancer. Current treatments can cause scarring and hypopigmentation, be inconvenient, or require long treatment duration. Non-invasive alternative therapy for treatment of AK lesions is thus being researched.
Eligibility
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Male patients at least 18 years of age.
- A contiguous 100 cm2 treatment area containing at least 5 AK lesions, on the either the right or left extensor (dorsal aspect) forearm.
- Written informed consent has been obtained.
- Agreement from the patient to allow photographs of the selected AK treatment area to be taken and used as part of the study package.
Contacts and Locations
More Information
Additional Information:
No publications provided
Keywords provided by Peplin:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on October 17, 2012
Additional Information:
Q-Pharm Ltd 
No publications provided
ClinicalTrials.gov Identifier: | NCT00544258 History of Changes |
Other Study ID Numbers: | PEP005-013 |
Study First Received: | October 14, 2007 |
Last Updated: | May 22, 2008 |
Health Authority: | Australia: Human Research Ethics Committee Australia: Department of Health and Ageing Therapeutic Goods Administration |
Keywords provided by Peplin:
Pharmacokinetic study Actinic Keratosis Topical Dermatology |
Additional relevant MeSH terms:
Keratosis Keratosis, Actinic Skin Diseases Precancerous Conditions Neoplasms |
ClinicalTrials.gov processed this record on October 17, 2012